Since it was first reported in 1912, acute coronary syndrome (ACS) has become the leading cause of death in the Western world. Several improvements that have been made over the years in the pharmacological treatment of ACS have reduced the relative risk of death due to myocardial infarction from 35-45% previously to approximately 3.5% at present. Universities, websites, and educational videos commonly use a mnemonic for morphine, oxygen, nitrates, and aspirin (MONA) to refer to the adjuvant treatment used for the management of ACS. We review the scientific data pertaining to treatment strategies for the management of ACS and discuss whether MONA remains relevant in the present scenario. While using morphine and oxygen is associated with risks such as higher mortality and increase in the size of the infarct, respectively, several available drugs such as fibrinolytics, anticoagulants, beta-blockers, renin-angiotensin-aldosterone system inhibitors, P2Y12 inhibitors, and statins are known to be useful to treat ACS. MONA should be viewed as an obsolete teaching and learning aid, and therefore we recommend that its use be discontinued for the management of ACS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866121PMC
http://dx.doi.org/10.7759/cureus.2114DOI Listing

Publication Analysis

Top Keywords

morphine oxygen
12
management acs
12
oxygen nitrates
8
pharmacological treatment
8
acute coronary
8
coronary syndrome
8
acs
6
nitrates mortality
4
mortality reducing
4
reducing pharmacological
4

Similar Publications

Opioid-induced respiratory depression: clinical aspects and pathophysiology of the respiratory network effects.

Am J Physiol Lung Cell Mol Physiol

December 2024

The author is retired. The positions and affiliations are those prior to his retirement.

Important insights and consensus remain lacking for risk prediction of opioid-induced respiratory depression (OIRD), reversal of respiratory depression (RD), the pathophysiology of OIRD, and which sites make the most significant contribution to its induction. The ventilatory response to inhaled carbon dioxide is the most sensitive biomarker of OIRD. To accurately predict respiratory depression (RD), a multivariant RD prospective trial using continuous capnograph and oximetry examining 5 independent variables: age ≥60, sex, opioid naivety, sleep disorders, and chronic heart failure (PRODIGY trial), was undertaken.

View Article and Find Full Text PDF

Introduction: Use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is still in the focus of research, in which pigs are commonly involved. During VA-ECMO, cardiovascular parameters are artificially manipulated and therefore not reliable indicators of nociception. Nociceptive withdrawal reflex (NWR) thresholds can be a suitable alternative in such a context.

View Article and Find Full Text PDF

[How I treat…the cardiogenic acute pulmonary oedema].

Rev Med Liege

December 2024

Service des Urgences, CHC Mont Légia, Liège, Belgique.

In the context of Acute Pulmonary Edema (APE), the old school moto was LMNOP, for "Lasix-Morphine-Nitrates-Oxygen-Positive Pressure". However, this mnemonic, while not entirely inaccurate, deserves revision or at least a slight reinterpretation. APE remains a well-known condition in emergency departments, with a high mortality rate.

View Article and Find Full Text PDF

Significance: Assessment of pain and its clinical diagnosis rely on subjective methods which become even more complicated under analgesic drug administrations.

Aim: We aim to propose a deep learning (DL)-based transfer learning (TL) methodology for objective classification of functional near-infrared spectroscopy (fNIRS)-derived cortical oxygenated hemoglobin responses to painful and non-painful stimuli presented under different timings post-analgesic and placebo drug administration.

Approach: A publicly available fNIRS dataset obtained during painful/non-painful stimuli was used.

View Article and Find Full Text PDF

The effects of low-dose morphine on sleep and breathlessness in COPD: A randomized trial.

Chest

December 2024

Flinders Health and Medical Research Institute/Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia.

Background: Low-dose morphine may be prescribed to reduce chronic breathlessness in chronic obstructive pulmonary disease (COPD). Recent subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!